{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:35:33Z","timestamp":1785317733614,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","award":["SEOM+1 grant (UGP-19-428)"],"award-info":[{"award-number":["SEOM+1 grant (UGP-19-428)"]}],"id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hereditary leiomyomatosis and renal cell cancer syndrome is a rare autosomal dominant hereditary syndrome. Previously, we published the largest cohort of <jats:italic>FH<\/jats:italic> mutation carriers in Spain and observed a highly recurrent missense heterozygous variant, <jats:italic>FH<\/jats:italic>(NM_000143.4):c.1118A\u2009&gt;\u2009G p.(Asn373Ser), in 104 individuals from 31 apparently unrelated families. Here, we aimed to establish its founder effect and characterize the associated clinical phenotype.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Haplotype analysis confirmed that families shared a common haplotype (32\/38 markers) spanning 0.61\u20130.82\u00a0Mb, indicating this recurrent variant was inherited from a founder ancestor. Cutaneous and uterine leiomyomatosis were diagnosed in 64.6% (64\/99) and 98% (50\/51) of patients, respectively, and renal cell cancer was present in 10.4% (10\/96). The pathogenic <jats:italic>FH<\/jats:italic>_c.1118A\u2009&gt;\u2009G variant is a Spanish founder mutation that originated 12\u201326 generations ago. We estimate that the variant may have appeared between 1370 and 1720. Individuals carrying this founder mutation had similar frequency of renal cell cancer and a higher frequency of renal cysts and leiomyomas than those in other cohorts of this syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the Spanish province of Alicante there is a high prevalence of HLRCC because of the founder mutation <jats:italic>FH<\/jats:italic> c.1118A\u2009&gt;\u2009G; p.(Asn373Ser). The characterization of founder mutations provides accurate and specific information regarding their penetrance and expressivity. In individuals with suspected HLRCC from the province of Alicante, genetic testing by direct analysis of the founder <jats:italic>FH<\/jats:italic> c.1118A\u2009&gt;\u2009G; p.(Asn373Ser) mutation may be a faster and more efficient diagnostic tool compared with complete gene sequencing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03017-z","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T09:02:35Z","timestamp":1706259755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-5374","authenticated-orcid":false,"given":"Ana Beatriz","family":"S\u00e1nchez-Heras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"D\u00e1maso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Castillejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Teul\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conxi","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"S\u00e1nchez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Z\u00fa\u00f1iga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e0","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ramon y Cajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Castillejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Perea","family":"Iba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Mart\u00ednez","family":"Sevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"S\u00e1nchez-Mira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Escandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Berbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"3017_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2340\/0001555553409416","volume":"53","author":"WB Reed","year":"1973","unstructured":"Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol. 1973;53:409\u201316.","journal-title":"Acta Derm Venereol"},{"key":"3017_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ng849","volume":"30","author":"IPM Tomlinson","year":"2002","unstructured":"Tomlinson IPM, Alam NA, Rowan AJ, Barclay E, Jaeger EEM, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406\u201310.","journal-title":"Nat Genet"},{"key":"3017_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archderm.141.2.199","volume":"141","author":"NA Alam","year":"2005","unstructured":"Alam NA, Barclay E, Rowan AJ, Tyrer JP, Calonje E, Manek S, et al. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Arch Dermatol. 2005;141:199\u2013206.","journal-title":"Arch Dermatol"},{"key":"3017_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/jmg.2010.085068","volume":"48","author":"B Gardie","year":"2011","unstructured":"Gardie B, Remenieras A, Kattygnarath D, Bombled J, Lefevre S, Perrier-Trudova V, et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet. 2011;48:226\u201334.","journal-title":"J Med Genet"},{"key":"3017_CR5","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1073\/pnas.051633798","volume":"98","author":"V Launonen","year":"2001","unstructured":"Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98:3387\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3017_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/cge.13014","volume":"92","author":"M Muller","year":"2017","unstructured":"Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, et al. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers: MULLER et al. Clin Genet. 2017;92:606\u201315.","journal-title":"Clin Genet"},{"key":"3017_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1086\/376435","volume":"73","author":"JR Toro","year":"2003","unstructured":"Toro JR, Nickerson ML, Wei M-H, Warren MB, Glenn GM, Turner ML, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95\u2013106.","journal-title":"Am J Hum Genet"},{"key":"3017_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jmg.2005.033506","volume":"43","author":"M-H Wei","year":"2005","unstructured":"Wei M-H. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2005;43:18\u201327.","journal-title":"J Med Genet"},{"key":"3017_CR9","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","volume":"23","author":"LJ Castro-Vega","year":"2014","unstructured":"Castro-Vega LJ, Buffet A, De Cubas AA, Casc\u00f3n A, Menara M, Khalifa E, et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet. 2014;23:2440\u20136.","journal-title":"Hum Mol Genet"},{"key":"3017_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/jmg.2005.036400","volume":"43","author":"HJ Lehtonen","year":"2006","unstructured":"Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, Salovaara R, Herva R, Koivisto PA, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet. 2006;43:523\u20136.","journal-title":"J Med Genet"},{"key":"3017_CR11","unstructured":"Coman D, Kranc KR, Christodoulou J. Fumarate Hydratase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2022 Apr 3]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1506\/"},{"key":"3017_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.euo.2019.11.002","volume":"3","author":"C Forde","year":"2020","unstructured":"Forde C, Lim DHK, Alwan Y, Burghel G, Butland L, Cleaver R, et al. Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals. Eur Urol Oncol. 2020;3:764\u201372.","journal-title":"Eur Urol Oncol"},{"key":"3017_CR13","doi-asserted-by":"publisher","first-page":"E3277","DOI":"10.3390\/cancers12113277","volume":"12","author":"AB S\u00e1nchez-Heras","year":"2020","unstructured":"S\u00e1nchez-Heras AB, Castillejo A, Garc\u00eda-D\u00edaz JD, Robledo M, Teul\u00e9 A, S\u00e1nchez R, et al. Hereditary leiomyomatosis and renal cell cancer syndrome in spain: clinical and genetic characterization. Cancers. 2020;12:E3277.","journal-title":"Cancers"},{"key":"3017_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1086\/383591","volume":"74","author":"TL Chan","year":"2004","unstructured":"Chan TL, Chan YW, Ho JWC, Chan C, Chan ASY, Chan E, et al. MSH2 c.1452\u20131455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population. Am J Hum Genet. 2004;74:1035\u201342.","journal-title":"Am J Hum Genet"},{"key":"3017_CR15","doi-asserted-by":"publisher","first-page":"D988","DOI":"10.1093\/nar\/gkab1049","volume":"50","author":"F Cunningham","year":"2022","unstructured":"Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, et al. Ensembl 2022. Nucleic Acids Res. 2022;50:D988\u201395.","journal-title":"Nucleic Acids Res"},{"key":"3017_CR16","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1101\/gr.229102","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12:996\u20131006.","journal-title":"Genome Res"},{"key":"3017_CR17","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1200\/JCO.2006.06.9443","volume":"25","author":"PM Machado","year":"2007","unstructured":"Machado PM, Brand\u00e3o RD, Cavaco BM, Eug\u00e9nio J, Bento S, Nave M, et al. Screening for a BRCA2 rearrangement in high-risk breast\/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol. 2007;25:2027\u201334.","journal-title":"J Clin Oncol"},{"key":"3017_CR18","unstructured":"Prevalence_of_rare_diseases_by_alphabetical_list.pdf [Internet]. [cited 2022 Apr 16]. https:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Prevalence_of_rare_diseases_by_alphabetical_list.pdf"},{"key":"3017_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/cncr.33997","volume":"128","author":"E Lu","year":"2022","unstructured":"Lu E, Hatchell KE, Nielsen SM, Esplin ED, Ouyang K, Nykamp K, et al. Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. Cancer. 2022;128:675\u201384.","journal-title":"Cancer"},{"key":"3017_CR20","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1002\/cncr.32914","volume":"126","author":"B Shuch","year":"2020","unstructured":"Shuch B, Li S, Risch H, Bindra RS, McGillivray PD, Gerstein M. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer. Cancer. 2020;126:3657\u201366.","journal-title":"Cancer"},{"key":"3017_CR21","unstructured":"Fumarate hydratase - ClinVar - NCBI [Internet]. [cited 2022 Apr 18]. https:\/\/www.ncbi.nlm.nih.gov\/clinvar?term=fumarate%20hydratase&cmd=correctspelling"},{"key":"3017_CR22","unstructured":"FH | gnomAD v2.1.1 | gnomAD [Internet]. [cited 2022 Apr 30]. https:\/\/gnomad.broadinstitute.org\/gene\/ENSG00000091483?dataset=gnomad_r2_1"},{"key":"3017_CR23","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","volume":"35","author":"C Kopanos","year":"2019","unstructured":"Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome: the human genomic variant search engine. Bioinforma Oxf Engl. 2019;35:1978\u201380.","journal-title":"Bioinforma Oxf Engl"},{"key":"3017_CR24","doi-asserted-by":"crossref","unstructured":"Chuang GS, Mart\u00ednez Mir A, Geyer A, Engler DE, Glaser B, Cserhalmi-Friedman PB, et al. Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata. American Academy of Dermatology; 2005 [cited 2022 Apr 30]; https:\/\/digital.csic.es\/handle\/10261\/39383","DOI":"10.1016\/j.jaad.2004.08.051"},{"key":"3017_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-020-01653-9","volume":"16","author":"Z Chayed","year":"2021","unstructured":"Chayed Z, Kristensen LK, Ousager LB, R\u00f8nlund K, Bygum A. Hereditary leiomyomatosis and renal cell carcinoma: a case series and literature review. Orphanet J Rare Dis. 2021;16:34.","journal-title":"Orphanet J Rare Dis"},{"key":"3017_CR26","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00345-018-2288-5","volume":"36","author":"ER Maher","year":"2018","unstructured":"Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol. 2018;36:1891\u20138.","journal-title":"World J Urol"},{"key":"3017_CR27","doi-asserted-by":"crossref","unstructured":"Thompson AJ, Alwan YM, Ramani VAC, Evans DG, Maher ER, Woodward ER. Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC). J Med Genet. 2022;jmedgenet-2021-108215.","DOI":"10.1136\/jmedgenet-2021-108215"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03017-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03017-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03017-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T09:06:59Z","timestamp":1706260019000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03017-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3017"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03017-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"assertion":[{"value":"22 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of the Hospital General Universitario de Elche on January 25, 2018 (code 42\/2017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors had no relevant conflicts of interest to this matter. Ana Beatriz Sanchez-Heras COI are: Consulting or Advisory Role (Clovis), Speakers' Bureau (AstraZeneca Spain; MSD; GlaxoSmithKline; Clovis), congress registration (MSD; GSK).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}